Cargando…

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

SIMPLE SUMMARY: Available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Despite this, the main issues remain to be addressed. First of all, a significant proportion of patients eventually relapse. The potential strategy t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martino, Massimo, Canale, Filippo Antonio, Alati, Caterina, Vincelli, Iolanda Donatella, Moscato, Tiziana, Porto, Gaetana, Loteta, Barbara, Naso, Virginia, Mazza, Massimiliano, Nicolini, Fabio, Ghelli Luserna di Rorà, Andrea, Simonetti, Giorgia, Ronconi, Sonia, Ceccolini, Michela, Musuraca, Gerardo, Martinelli, Giovanni, Cerchione, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197914/ https://www.ncbi.nlm.nih.gov/pubmed/34072068 http://dx.doi.org/10.3390/cancers13112639

Ejemplares similares

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2020)

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)

The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
por: Canale, Filippo A., et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
por: Martino, Massimo, et al.
Publicado: (2022)

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2023)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
por: Padella, Antonella, et al.
Publicado: (2022)

The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
por: Cerchione, C., et al.
Publicado: (2022)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
por: Cerchione, C., et al.
Publicado: (2022)

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
por: Cerchione, Claudio, et al.
Publicado: (2020)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

An (1)H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia
por: Cerchione, Claudio, et al.
Publicado: (2020)

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2021)

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
por: Beeharry, Neil, et al.
Publicado: (2015)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL
por: Cerchione, Claudio, et al.
Publicado: (2023)

P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL
por: Cerchione, Claudio, et al.
Publicado: (2023)

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
por: De Matteis, Serena, et al.
Publicado: (2018)

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

The Role of MicroRNA in Graft-Versus-Host-Disease: A Review
por: Pitea, Martina, et al.
Publicado: (2023)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?
por: Martino, Massimo, et al.
Publicado: (2023)

Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes
por: Pallotti, Maria Caterina, et al.
Publicado: (2021)

How I Manage Chronic Lymphocytic Leukemia
por: Nasnas, Patrice, et al.
Publicado: (2023)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_869tcsmagcjjiq7pm1751bpdch